Antipsychotic drugs

Serotonin Reuptake Inhibitor Use, Depression, and Long-Term Outcomes After an Acute Coronary Syndrome: A Prospective Cohort Study.

Published May 25, 2013

Serotonin Reuptake Inhibitor Use, Depression, and Long-Term Outcomes After an Acute Coronary Syndrome: A Prospective Cohort Study.

JAMA Intern Med. 2013 May 13; 1-2
Rieckmann N, Kronish IM, Shapiro PA, Whang W, Davidson KW

HubMed – depression

Rapid… Continue reading →

Mitochondrial Dysfunction, Oxidative Stress, and Major Depressive Disorder.

Published May 8, 2013

Mitochondrial dysfunction, oxidative stress, and major depressive disorder.

Neuropsychiatr Dis Treat. 2013; 9: 567-73
Tobe EH

There is controversy about depression being a physical illness, in part because a reproducible, sensitive, and specific biologic marker is not available. However,… Continue reading →

Luteolin Is a Novel P90 Ribosomal S6 Kinase (RSK) Inhibitor That Suppresses Notch4 Signaling by Blocking the Activation of Y-Box Binding Protein-1 (YB-1).

Published April 18, 2013

Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).

Oncotarget. 2013 Feb; 4(2): 329-45
Reipas KM, Law JH, Couto N, Islam S, Li Y, Li… Continue reading →

Mild Traumatic Brain Injury Among the Geriatric Population.

Published April 17, 2013

Mild Traumatic Brain Injury among the Geriatric Population.

Curr Transl Geriatr Exp Gerontol Rep. 2012 Sep 1; 1(3): 135-142
Papa L, Mendes ME, Braga CF

Mild traumatic brain injury (TBI) is an unfortunately common occurrence in the elderly. With… Continue reading →

Adherence Challenges and Long-Acting Injectable Antipsychotic Treatment in Patients With Schizophrenia.

Published April 3, 2013

Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.

J Psychosoc Nurs Ment Health Serv. 2013 Mar; 51(3): 13-8
Kirk Morton N, Zubek D

Medication nonadherence has been associated with persistence of psychotic symptoms, relapse, and hospitalization… Continue reading →

Methamphetamine and Parkinson’s Disease.

Published March 12, 2013

Methamphetamine and Parkinson’s disease.

Parkinsons Dis. 2013; 2013: 308052
Granado N, Ares-Santos S, Moratalla R

Parkinson’s disease (PD) is a neurodegenerative disorder predominantly affecting the elderly. The aetiology of the disease is not known, but age and environmental factors… Continue reading →

Functional and Structural Neural Network Characterization of Serotonin Transporter Knockout Rats.

Published March 2, 2013

Functional and structural neural network characterization of serotonin transporter knockout rats.

PLoS One. 2013; 8(2): e57780
van der Marel K, Homberg JR, Otte WM, Dijkhuizen RM

Brain serotonin homeostasis is crucially maintained by the serotonin transporter (5-HTT), and its… Continue reading →

Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex.

Published February 26, 2013

Vigabatrin Inhibits Seizures and mTOR Pathway Activation in a Mouse Model of Tuberous Sclerosis Complex.

PLoS One. 2013; 8(2): e57445
Zhang B, McDaniel SS, Rensing NR, Wong M

Epilepsy is a common neurological disorder and cause of significant morbidity… Continue reading →

Depression Treatment: Treatment of Huntington Disease.

Published February 20, 2013

Treatment of Huntington Disease.

Filed under: Depression Treatment

Curr Treat Options Neurol. 2013 Feb 16;
Videnovic A

OPINION STATEMENT: Many pharmacological agents have been utilized in the treatment of Huntington disease (HD). Several excellent reviews about the treatment of… Continue reading →